Point72 Asset Management
ELEV

Point72 Asset Management’s Elevation Oncology ELEV Stock Holding History

Point72 Asset Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,680,230
Closed -$4.54M – 2077
2024
Q2 		$4.54M Sell
1,680,230
-1,687,970
-50% -$6.36M 0.01% 859
2024
Q1 		$17.3M Buy
+3,368,200
New +$10.9M 0.04% 496
2023
Q3 		– Sell
-400,000
Closed -$608K – 2564
2023
Q2 		$608K Buy
+400,000
New +$1.05M ﹤0.01% 1228
2021
Q3 		– Sell
-50,000
Closed -$679K – 1090
2021
Q2 		$679K Buy
+50,000
New +$618K ﹤0.01% 846

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Point72 Asset Management's ELEV Position: Q3 2024 in Review

Point72 Asset Management sold out of Elevation Oncology (ELEV) in Q3 2024, closing a stake of 1,680,230 shares — an estimated $4.54M sold.

Point72 Asset Management first reported a position in ELEV in Q2 2021 and held it in 4 quarters. The position peaked at $17.3M in Q1 2024. 68 funds tracked by Wall St. Rank hold ELEV as of Q3 2024.

  • Point72 Asset Management reported no remaining Elevation Oncology position as of Q3 2024 after selling out during the quarter.
  • Point72 Asset Management sold 1,680,230 Elevation Oncology shares in Q3 2024, an estimated $4.54M.
  • Point72 Asset Management first reported a position in Elevation Oncology in Q2 2021 and held it in 4 quarters.
  • Point72 Asset Management's Elevation Oncology position peaked at $17.3M in Q1 2024.
  • 68 funds tracked by Wall St. Rank held Elevation Oncology as of Q3 2024.

Based on Point72 Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.